Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

1.

First 100 cases at a low volume prostate brachytherapy institution: learning curve and the importance of continuous quality improvement.

Bockholt NA, DeRoo EM, Nepple KG, Modrick JM, Smith MC, Fallon B, Hass AC, Tracy CR, Brown JA.

Can J Urol. 2013 Oct;20(5):6907-12.

PMID:
24128827
[PubMed - in process]
2.

Isotope selection for patients undergoing prostate brachytherapy.

Cha CM, Potters L, Ashley R, Freeman K, Wang XH, Waldbaum R, Leibel S.

Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):391-5.

PMID:
10487561
[PubMed - indexed for MEDLINE]
3.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
[PubMed - indexed for MEDLINE]
4.

Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution.

Lee WR, deGuzman AF, Bare RL, Marshall MG, McCullough DL.

Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):83-8.

PMID:
10656377
[PubMed - indexed for MEDLINE]
5.

A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.

Potters L, Cao Y, Calugaru E, Torre T, Fearn P, Wang XH.

Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):605-14.

PMID:
11395226
[PubMed - indexed for MEDLINE]
6.

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73.

PMID:
11849788
[PubMed - indexed for MEDLINE]
7.

The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E.

Cancer J. 2005 May-Jun;11(3):234-40.

PMID:
16053667
[PubMed - indexed for MEDLINE]
8.

Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.

Lettmaier S, Lotter M, Kreppner S, Strnad A, Fietkau R, Strnad V.

Radiother Oncol. 2012 Aug;104(2):181-6. doi: 10.1016/j.radonc.2012.07.003. Epub 2012 Jul 30.

PMID:
22853851
[PubMed - indexed for MEDLINE]
9.

The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer.

Ash D, Al-Qaisieh B, Bottomley D, Carey B, Joseph J.

Radiother Oncol. 2006 May;79(2):185-9. Epub 2006 May 15.

PMID:
16701911
[PubMed - indexed for MEDLINE]
10.

Influence of prostate volume on dosimetry results in real-time 125I seed implantation.

McNeely LK, Stone NN, Presser J, Chircus JH, Stock RG.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):292-9.

PMID:
14697451
[PubMed - indexed for MEDLINE]
11.

Validation and comparison of the two Kattan nomograms in patients with prostate cancer treated with (125) iodine brachytherapy.

Kaplan A, German L, Chen J, Matzkin H, Mabjeesh NJ.

BJU Int. 2012 Jun;109(11):1661-5. doi: 10.1111/j.1464-410X.2011.10748.x. Epub 2011 Nov 24.

PMID:
22115188
[PubMed - indexed for MEDLINE]
12.

Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.

Merrick GS, Butler WM, Galbreath RW, Lief JH.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):41-8.

PMID:
11516849
[PubMed - indexed for MEDLINE]
13.

Potential role of various dosimetric quality indicators in prostate brachytherapy.

Merrick GS, Butler WM, Dorsey AT, Lief JH.

Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):717-24.

PMID:
10348304
[PubMed - indexed for MEDLINE]
14.

Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.

Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G.

Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):61-9.

PMID:
11163498
[PubMed - indexed for MEDLINE]
15.

The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer.

Ash D, Al-Qaisieh B, Bottomley D, Carey B, Joseph J.

Radiother Oncol. 2005 Jun;75(3):303-6.

PMID:
15890423
[PubMed - indexed for MEDLINE]
16.

Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis.

Snyder KM, Stock RG, Hong SM, Lo YC, Stone NN.

Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):335-41.

PMID:
11380219
[PubMed - indexed for MEDLINE]
17.

Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.

Gondi V, Deutsch I, Mansukhani M, O'Toole KM, Shah JN, Schiff PB, Katz AE, Benson MC, Goluboff ET, Ennis RD.

Urology. 2007 Mar;69(3):541-6.

PMID:
17382161
[PubMed - indexed for MEDLINE]
18.

A comprehensive review of prostate cancer brachytherapy: defining an optimal technique.

Vicini FA, Kini VR, Edmundson G, Gustafson GS, Stromberg J, Martinez A.

Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):483-91. Review.

PMID:
10348275
[PubMed - indexed for MEDLINE]
19.

Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.

Stock RG, Stone NN, Cesaretti JA.

Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):448-53.

PMID:
12738319
[PubMed - indexed for MEDLINE]
20.

Report on the early efficacy and tolerability of I(125) permanent prostate brachytherapy from a UK multi-institutional database.

Mitchell DM, Mandall P, Bottomley D, Hoskin PJ, Logue JP, Ash D, Ostler P, Elliott T, Henry A, Wylie JP.

Clin Oncol (R Coll Radiol). 2008 Dec;20(10):738-44. doi: 10.1016/j.clon.2008.09.003. Epub 2008 Oct 31.

PMID:
18951769
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk